Madrigal Pharmaceuticals

Major Drugs - Conshohocken, PA, US

Madrigal Pharmaceuticals Employees
Remy Sukhija

Chief Commercial Officer

Contact Remy Sukhija

Karen PhD

Medical Science Liaison

Contact Karen PhD

Caitlin MS

Senior Clinical Research Associate

Contact Caitlin MS

Sandy Soulakian

Associate Director Clinical Supplies

Contact Sandy Soulakian

Yvette Peters

Sr. Director, Regulatory Medical Writing

Contact Yvette Peters

Steven Dzierba

Field Director-West, Medical Affairs

Contact Steven Dzierba

View All Madrigal Pharmaceuticals Employees Contact All Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals Details

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy.Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial.A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.For more information about Madrigal, please visit out website at https://www.madrigalpharma.com/ and follow us on Twitter at @MadrigalPharma.

Madrigal Pharmaceuticals logo, Madrigal Pharmaceuticals contact details
Employees: 50 - 99
HQ: 484-380-9263
Location: Conshohocken, PA, US
Revenue: 5 - 10 Million
Biotechnology Cleantech Healthcare Pharmaceuticals Wind Power Major Drugs Pharmaceutical Preparations
Madrigal Pharmaceuticals Technologies
Load Balancers

Nginx

CMS

Drupal

Other

Microsoft Office 365

Hosting

Amazon AWS

Email Delivery

Amazon SES

View All Technologies Used At Madrigal Pharmaceuticals

Contacting Madrigal Pharmaceuticals: Connect with Executives and Employees

Get in Touch with Madrigal Pharmaceuticals Executives and Employees

Connecting with Madrigal Pharmaceuticals's Executives and Workforce

Accessing Contact Information for Madrigal Pharmaceuticals Executives

Connecting with Madrigal Pharmaceuticals: Reach Out to Their Team

Discover How to Contact Madrigal Pharmaceuticals Executives and Staff

Looking to connect with Madrigal Pharmaceuticals executives or employees?

Seeking to Get in Touch with Madrigal Pharmaceuticals Executives or Staff?

Want to Reach Out to Madrigal Pharmaceuticals Executives or Team Members?

In Search of Contact Details for Madrigal Pharmaceuticals Professionals?

Connecting with Madrigal Pharmaceuticals: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z